The Race to the Bottom Line - Research Report on Endo Health Solutions Inc., Warner Chilcott Public Limited Company, The Gap, Inc., Guess?, Inc. and Alto Networks, Inc. PR Newswire NEW YORK, February 20, 2013 NEW YORK, February 20, 2013 /PRNewswire/ -- Today, National Traders Association announced new research reports highlighting Endo Health Solutions Inc. (NASDAQ: ENDP), Warner Chilcott Public Limited Company (NASDAQ: WCRX), The Gap, Inc. (NYSE:GPS), Guess? Inc. (NYSE:GES) and Alto Networks, Inc. (NYSE: PANW). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. ENDO HEALTH SOLUTIONS INC. Research Report The patents Lidoderm patch and Opana ER tablets are due to expire. Lidoderm had sales of $825 million in 2011 and this accounted for 30 percent of the company's revenues. Furthermore, with more deaths arising from painkiller overdose, regulators have been looking more closely on how painkiller manufacturers have been handling their products. The company is setting aside $194 million to cover possible penalties because of a federal investigation into how the company promoted and sold its Lidoderm patch painkilling drug. But if ever Endo Health Solutions pushes through with the talks that it will be put on sale, it could present new opportunities for its company as well as its potential buyer, Warner Chilcott. Warner Chilcott, being a Canadian company, will benefit from better tax rates. This would create a stronger cash flow and increase the value of both companies. The Full Research Report on Endo Health Solutions Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/e000_ENDP] -- WARNER CHILCOTT PUBLIC LIMITED COMPANY Research Report After separating from Warner-Lambert in 1996, Warner Chilcott has evolved to become a fully integrated pharmaceutical company with a broad portfolio of leading branded products. However, Wall Street has not been kind to Warner Chilcott in the past year. It had put itself on sale early in 2012, much to investors' delight, but dropped the sale in August. To make matters more difficult, Warner Chilcott's acne treatment drug Doryx is facing generic competition, while Enablex and oral contraceptive Loestrin could both lose their patents by 2015. Nevertheless, Warner Chilcott CFO Paul Herenden comments that the company still has strong strategies for its key franchises. Herendeen asserted that the company is working on improved versions of its existing products and are developing new products such as a Phase 2 product for rosacea and acne, and a Phase 3 treatment for erectile dysfunction. The same threat of generic competition exists for Endo. The patents Lidoderm patch and Opana ER tablets are due to expire. Lidoderm had sales of $825 million in 2011 and this accounted for 30 percent of the company's revenues. The Full Research Report on Warner Chilcott Public Limited Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/5d83_WCRX] -- THE GAP, INC. Research Report Gap opened its first outlet stores in China in the latter part of 2012, and is expected to produce tremendous growth like how competitors Abercrombie & Fitch and high-end retailer Coach have performed in the country with their stores. In addition, Gap's namesake brand and its higher-priced banana republic brand would easily expand there with a significant lack of competition. In addition, Trefis predicts that the company's European and Japanese sales could improve this year, as the European Commission expects a gradual improvement in the region's economy this year until 2014, while the launch of e-commerce will help improve sales from the still-recovering Japan.A report from India Times indicates that Gap is set to open up stores in the Indian subcontinent soon, as rival retailers H&M and Zara also penetrate the potentially lucrative market. The country's middle class has been growing steadily for being a popular outsourcing destination for more than a decade now. The Full Research Report on The Gap, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/e8c3_GPS] -- GUESS?, INC. Research Report Meanwhile, Guess has seen its Asian business post exponential growth amid a relatively weak fiscal year. However, its revenues from that market comprise only about 10 percent of Guess' total revenue of $250 million for the previous quarter. The growth is driven by its aggressive expansion during fiscal Q3 for this year, opening 21 stores and 45 concession shops, with an additional 40 in its planning stages. Guess also partnered with a Chinese licensee, positioning itself in China to fuel long-term growth. Its licensing business has also been growing while its competitors are struggling in that segment, banking on only its strong brand recognition to maintain its asset-light high-margin segment. In addition, the retailer is making a big push into Spain, Germany, Northern Europe, and Russia over the next five years as the EU reports a positive economic outlook in that period. The move further diversifies the company away from the US, and is expected to generate more international sales than local. The Full Research Report on Guess?, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/6949_GES] -- ALTO NETWORKS, INC. Research Report On the other hand, Palo Alto Networks closed its fiscal fourth quarter of 2012 by achieving $75.6 million, a significant increase compared with $40.2 million in the fiscal fourth quarter of 2011. The company also reported $4.6 million net loss in the fiscal year of 2012, or 18 cents per basic and diluted share, against its net loss of $6 million, or 40 cents per basic and diluted share, in the same quarter of 2011. These improvements continue to push the two companies' present performance in the recent market close as Palo Alto Networks' shares climbed $1.43 or 2.65%, to $55.36. The Full Research Report on Alto Networks, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/6bd4_PANW] -- Consider National Traders Association Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks. Contact: Demi Lapierre Email: press@NationalTradersAssociation.org Main: +1-(702)-212-4493 SOURCE National Traders Association
The Race to the Bottom Line - Research Report on Endo Health Solutions Inc., Warner Chilcott Public Limited Company, The Gap,
Press spacebar to pause and continue. Press esc to stop.